Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b 3-way Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Once Daily Doses of PUR1800 in Adult Patients With Stable Chronic Obstructive Pulmonary Disease

Next Previous
Trial Profile

A Phase 1b 3-way Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Once Daily Doses of PUR1800 in Adult Patients With Stable Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PUR 1800 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pulmatrix

Most Recent Events

  • 27 Feb 2023 Results assessing safety, tolerability and pharmacoki-netics of inhaled doses of PUR1800 for 14 days in patients with stable and1+ years of Grade II/III COPD presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 23 Jan 2023 According to a Pulmatrix media release, data from this study will be presented by Margaret Wasilewski MD, at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 10 Nov 2022 According to a Pulmatrix media release, the company is analyzing data from the trial for presentation at a relevant medical conference in 2023. These data will inform the design of a potential Phase 2 study in the treatment of AECOPD.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top